[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

UY39060A - Composiciones y métodos para prevenir y tratar la infección por coronavirus - vacunas sars-cov-2 - Google Patents

Composiciones y métodos para prevenir y tratar la infección por coronavirus - vacunas sars-cov-2

Info

Publication number
UY39060A
UY39060A UY0001039060A UY39060A UY39060A UY 39060 A UY39060 A UY 39060A UY 0001039060 A UY0001039060 A UY 0001039060A UY 39060 A UY39060 A UY 39060A UY 39060 A UY39060 A UY 39060A
Authority
UY
Uruguay
Prior art keywords
coronavirus
vaccines
compositions
cov
sars
Prior art date
Application number
UY0001039060A
Other languages
English (en)
Inventor
H Barouch Dan
C Sadoff Jerald
Petrus Maria Langedijk Johannes
Lucy Rutten
Johannes Gerardus BAKKERS Mark
Rinke Bos
Frank Wegmann
Adrianus Theodorus Maria Zuijdgeest David
An Vandebosch
Claude Michel LE GARS Mathieu
Original Assignee
Janssen Pharmaceuticals Inc
Beth Israel Deaconess Medical Ct Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA3101131A external-priority patent/CA3101131A1/en
Application filed by Janssen Pharmaceuticals Inc, Beth Israel Deaconess Medical Ct Inc filed Critical Janssen Pharmaceuticals Inc
Publication of UY39060A publication Critical patent/UY39060A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Refiere a composiciones inmunogénicas y vacunas conteniendo una proteína de coronavirus o un polinucleótido que codifica una proteína de coronavirus y sus usos. Proporciona métodos para tratar y / o prevenir infección por coronavirus mediante administración de una composición inmunogénica o vacuna al sujeto. Proporciona métodos para detectar y / o monitorear respuesta protectora de anticuerpos anticoronavirus (Ej.: respuesta de anticuerpos neutralizantes anti-coronavirus, anti-2019-nCoV, anti-Spike y / o anti-Spike). Refiere a un ácido nucleico aislado y / o recombinante que codifica una proteína de coronavirus S, a las proteínas de coronavirus S y al uso de las mismas en vacunas.
UY0001039060A 2020-01-31 2021-02-01 Composiciones y métodos para prevenir y tratar la infección por coronavirus - vacunas sars-cov-2 UY39060A (es)

Applications Claiming Priority (21)

Application Number Priority Date Filing Date Title
US202062969008P 2020-01-31 2020-01-31
US202062994630P 2020-03-25 2020-03-25
US202063014467P 2020-04-23 2020-04-23
US202063025782P 2020-05-15 2020-05-15
US202062705187P 2020-06-15 2020-06-15
US202062705308P 2020-06-21 2020-06-21
US202063043090P 2020-06-23 2020-06-23
US202062706366P 2020-08-12 2020-08-12
US202063066147P 2020-08-14 2020-08-14
US202062706676P 2020-09-02 2020-09-02
US202062706937P 2020-09-18 2020-09-18
US202062706958P 2020-09-21 2020-09-21
US202063198089P 2020-09-28 2020-09-28
US202063198306P 2020-10-09 2020-10-09
US202063112900P 2020-11-12 2020-11-12
CA3101131A CA3101131A1 (en) 2020-01-31 2020-11-28 Compositions and methods for preventing and treating coronavirus infection - sars­cov-2 vaccines
US202063121482P 2020-12-04 2020-12-04
US202163133969P 2021-01-05 2021-01-05
US202163135182P 2021-01-08 2021-01-08
US202163141913P 2021-01-26 2021-01-26
US202163142977P 2021-01-28 2021-01-28

Publications (1)

Publication Number Publication Date
UY39060A true UY39060A (es) 2021-10-29

Family

ID=77079265

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001039060A UY39060A (es) 2020-01-31 2021-02-01 Composiciones y métodos para prevenir y tratar la infección por coronavirus - vacunas sars-cov-2

Country Status (9)

Country Link
US (3) US20230075527A1 (es)
EP (1) EP4097122A4 (es)
JP (1) JP2023512519A (es)
KR (1) KR20220134622A (es)
CN (1) CN116096732A (es)
BR (1) BR112022014808A2 (es)
TW (1) TW202204380A (es)
UY (1) UY39060A (es)
WO (1) WO2021155323A1 (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210260181A1 (en) * 2014-09-16 2021-08-26 Altimmune, Inc Coronavirus immunogenic compositions and uses thereof
US10953089B1 (en) 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations
CN116096732A (zh) 2020-01-31 2023-05-09 贝斯以色列护理医疗中心有限公司 用于预防和治疗冠状病毒感染的组合物和方法-sars-cov-2疫苗
US11241493B2 (en) 2020-02-04 2022-02-08 Curevac Ag Coronavirus vaccine
US20240277830A1 (en) 2020-02-04 2024-08-22 CureVac SE Coronavirus vaccine
KR20220143684A (ko) 2020-02-07 2022-10-25 알엔에이이뮨, 인코포레이티드 신종 코로나바이러스 감염에 대한 mRNA 백신의 조성물 및 방법
EP4103228A1 (en) * 2020-02-13 2022-12-21 Institut Pasteur Nucleic acid vaccine against the sars-cov-2 coronavirus
JP2023514249A (ja) * 2020-02-14 2023-04-05 アルティミューン インコーポレーティッド コロナウイルス免疫原性組成物およびその使用
AU2021226567A1 (en) 2020-02-25 2022-10-13 Inovio Pharmaceuticals, Inc. Vaccines against coronavirus and methods of use
US11213482B1 (en) * 2020-03-05 2022-01-04 University of Pittsburgh—Of the Commonwealth System of Higher Educat SARS-CoV-2 subunit vaccine and microneedle array delivery system
JP2023522249A (ja) 2020-04-22 2023-05-29 ビオンテック・ソシエタス・エウロパエア コロナウイルスワクチン
JP2023524112A (ja) * 2020-04-29 2023-06-08 シ－ロン ルー， 唾液におけるウイルス検査
AU2021279312A1 (en) * 2020-05-29 2022-12-15 CureVac SE Nucleic acid based combination vaccines
WO2021249116A1 (en) 2020-06-10 2021-12-16 Sichuan Clover Biopharmaceuticals, Inc. Coronavirus vaccine compositions, methods, and uses thereof
EP4179328A2 (en) * 2020-07-10 2023-05-17 Covid Diagnostics Ltd. Compositions, methods, and systems for detecting immune response
WO2022020234A2 (en) * 2020-07-20 2022-01-27 Bio-Rad Laboratories, Inc. Immunoassay for sars-cov-2 neutralizing antibodies and materials therefor
US20220193225A1 (en) * 2020-08-31 2022-06-23 Bruce Lyday Compositions and methods for sars-2 vaccine with virus replicative particles and recombinant glycoproteins
US20240156946A1 (en) 2020-12-22 2024-05-16 CureVac SE Rna vaccine against sars-cov-2 variants
WO2022159433A1 (en) * 2021-01-20 2022-07-28 Singh Biotechnology, Llc Therapeutics directed against coronavirus
JP2022116482A (ja) * 2021-01-29 2022-08-10 東亞合成株式会社 ＳＡＲＳ－ＣｏＶ－２由来のアミノ酸配列およびその利用
MX2023011227A (es) 2021-03-22 2023-12-06 Recode Therapeutics Inc Composiciones y metodos para administracion dirigida a celulas.
MX2023011163A (es) * 2021-03-22 2024-02-27 Novavax Inc Formulaciones para vacuna contra coronavirus.
EP4333887A1 (en) * 2021-05-05 2024-03-13 Inovio Pharmaceuticals, Inc. Vaccines against coronavirus and methods of use
CN113832168B (zh) * 2021-08-15 2023-08-04 北京科兴中维生物技术有限公司 mRNA疫苗及其制备方法和应用
WO2023020939A1 (en) * 2021-08-17 2023-02-23 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
WO2023026182A1 (en) * 2021-08-24 2023-03-02 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
WO2023023940A1 (zh) * 2021-08-24 2023-03-02 复旦大学 一种诱导广谱抗冠状病毒的t细胞疫苗免疫原及其应用
CN116041534A (zh) * 2021-08-26 2023-05-02 江苏瑞科生物技术股份有限公司 新型冠状病毒免疫原性物质、其制备方法和应用
CN113913464B (zh) * 2021-09-28 2022-11-22 武汉枢密脑科学技术有限公司 一种表达载体、重组腺相关病毒及其在制备2019新型冠状病毒疫苗中的应用
WO2023092100A2 (en) * 2021-11-19 2023-05-25 Meissa Vaccines, Inc. Methods of administering chimeric vaccines
CN116178527A (zh) * 2021-11-26 2023-05-30 深圳先进技术研究院 抗sar-cov-2全人源单克隆抗体6g18及其制法与应用
IL313254A (en) * 2021-11-30 2024-08-01 Novavax Inc Vaccine formulations against corona
TWI843471B (zh) * 2022-03-11 2024-05-21 財團法人國家衛生研究院 含抗原和dna之組成物及其用途
CN114574502B (zh) * 2022-04-11 2023-07-14 四川大学 一种以复制缺陷腺相关病毒为载体的新型冠状病毒疫苗
WO2023198815A1 (en) 2022-04-14 2023-10-19 Janssen Vaccines & Prevention B.V. Sequential administration of adenoviruses
TW202400635A (zh) * 2022-04-20 2024-01-01 美商因諾維奧製藥公司 針對sars-cov-2變異體之免疫原性組合物及其使用方法
WO2023212446A1 (en) * 2022-04-29 2023-11-02 Xequel Bio, Inc. Compositions and methods for treating complications of viral infections and other respiratory disorders
WO2023240278A2 (en) * 2022-06-10 2023-12-14 The Trustees Of Columbia University In The City Of New York Uses of glycolipids as a vaccine adjuvant and methods thereof
US11654121B1 (en) 2022-06-22 2023-05-23 Flagship Pioneering Innovations Vi, Llc Combination therapies for the treatment of viral infections
WO2023250111A1 (en) 2022-06-22 2023-12-28 Flagship Pioneering Innovations Vi, Llc Combination therapies for the treatment of viral infections
US11878055B1 (en) 2022-06-26 2024-01-23 BioNTech SE Coronavirus vaccine
CN116942807A (zh) * 2022-07-07 2023-10-27 成都威斯克生物医药有限公司 抗SARS-CoV-2或其突变体感染的药物组合物及其联合用药物
CN118119646A (zh) * 2022-08-08 2024-05-31 神州细胞工程有限公司 一种可诱导广谱中和活性重组五组分新冠病毒三聚体蛋白疫苗的制备及应用
WO2024076805A2 (en) * 2022-10-07 2024-04-11 Zeptometrix Llc Control for protein-based assay
WO2024097259A1 (en) * 2022-11-01 2024-05-10 RNAimmune, Inc. Composition and methods for mrna vaccines against novel omicron coronavirus infections
CN116024269B (zh) * 2022-11-18 2024-02-02 复百澳(苏州)生物医药科技有限公司 一种冠状病毒假病毒颗粒的制备方法

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
US5298416A (en) 1989-01-18 1994-03-29 British Technology Group Ltd. Attenuated polioviruses
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
JP3602530B2 (ja) 1991-03-07 2004-12-15 ヴァイロジェネティクス コーポレイション 遺伝子操作したワクチン菌株
US5505947A (en) 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US5801030A (en) 1995-09-01 1998-09-01 Genvec, Inc. Methods and vectors for site-specific recombination
FR2751343B1 (fr) 1996-07-16 1998-12-18 Transgene Sa Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament
WO1998010087A1 (en) 1996-09-06 1998-03-12 Trustees Of The University Of Pennsylvania Chimpanzee adenovirus vectors
US6210683B1 (en) 1997-09-05 2001-04-03 Merck & Co., Inc. Stabilizers containing recombinant human serum albumin for live virus vaccines
BR9908015A (pt) 1998-02-17 2001-04-24 Schering Corp Composições que compreendem vìrus e métodos para concentração de preparações de vìrus
ES2323991T3 (es) 1998-11-16 2009-07-28 Introgen Therapeutics, Inc. Formulacion de adenovirus para terapia genica.
US6225289B1 (en) 1998-12-10 2001-05-01 Genvec, Inc. Methods and compositions for preserving adenoviral vectors
DE60034478T2 (de) 1999-11-16 2008-01-10 Genzyme Corp., Cambridge Vektoren und transgene mit regulatorischen elementen zur genverabreichung in leber
CA2399321C (en) 2000-03-07 2013-04-30 Robert K. Evans Adenovirus formulations
US6808905B2 (en) 2001-05-14 2004-10-26 Cell Genesys, Inc. Lentiviral vectors encoding clotting factors for gene therapy
EP1453537A1 (en) 2001-12-12 2004-09-08 FH Faulding & Co. Limited Composition for viral preservation
RU2004125283A (ru) 2002-01-18 2005-06-10 Шеринг Акциенгезельшафт (De) Стабилизированные композиции аденовируса
US20030180936A1 (en) 2002-03-15 2003-09-25 Memarzadeh Bahram Eric Method for the purification, production and formulation of oncolytic adenoviruses
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
WO2005005596A2 (en) * 2003-06-18 2005-01-20 Chinese National Human Genome Center At Shanghai Characterization of the earliest stages of the severe acute respiratory syndrome (sars) virus and uses thereof
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
KR101206206B1 (ko) 2003-07-22 2012-11-29 크루셀 홀란드 비.브이. 사스-코로나바이러스에 대한 결합분자 및 그것의 용도
EP1660016A4 (en) 2003-08-04 2008-04-16 Univ Massachusetts NUCLEIC ACIDS, PROTEINS, SARS VACCINES AND USES THEREOF
US7129042B2 (en) 2003-11-03 2006-10-31 Diagnostic Hybrids, Inc. Compositions and methods for detecting severe acute respiratory syndrome coronavirus
CA3028774A1 (en) 2004-01-23 2005-08-04 Msd Italia S.R.L. Chimpanzee adenovirus vaccine carriers
EA010433B1 (ru) 2004-10-13 2008-08-29 Круселл Холланд Б.В. Усовершенствованные аденовирусные векторы и их применение
EP1827502A4 (en) 2004-12-01 2008-01-16 Genzyme Corp PROCESS FOR THE TARGETED DELIVERY OF GENETIC MATERIAL TO THE LIVER
CA2620874A1 (en) 2005-08-23 2007-03-01 The Regents Of The University Of California Polyvalent vaccine
WO2007104792A2 (en) 2006-03-16 2007-09-20 Crucell Holland B.V. Recombinant adenoviruses based on serotype 26 and 48, and use thereof
EP1998804B1 (en) 2006-03-27 2014-04-16 Crucell Holland B.V. Compositions comprising a recombinant adenovirus and an adjuvant
US10041049B2 (en) 2008-11-03 2018-08-07 Janssen Vaccines & Prevention B.V. Method for the production of adenoviral vectors
AU2009316629B2 (en) 2008-11-18 2016-02-04 Beth Israel Deaconess Medical Center Antiviral vaccines with improved cellular immunogenicity
NZ594355A (en) 2009-02-02 2012-11-30 Okairos Ag Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
WO2010085984A1 (en) 2009-02-02 2010-08-05 Okairos Ag Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
CN102762721B (zh) 2010-02-15 2015-03-11 克鲁塞尔荷兰公司 用于生产Ad26腺病毒载体的方法
EP2655604B1 (en) 2010-12-14 2018-05-09 The Government of The United States of America as represented by The Secretary of The Department of Health and Human Services Adenovirus serotype 26 and serotype 35 filovirus vaccines
GB201108879D0 (en) 2011-05-25 2011-07-06 Isis Innovation Vector
EP3532095A1 (en) * 2016-10-25 2019-09-04 The U.S.A. as represented by the Secretary, Department of Health and Human Services Prefusion coronavirus spike proteins and their use
CN110268061B (zh) 2017-02-09 2024-07-16 扬森疫苗与预防公司 用于表达异源基因的有效的短启动子
EP3595676A4 (en) * 2017-03-17 2021-05-05 Modernatx, Inc. RNA VACCINES AGAINST ZOONOSES
GB201708444D0 (en) 2017-05-26 2017-07-12 Univ Oxford Innovation Ltd Compositions and methods for inducing an immune response
CN111295449B (zh) 2017-10-31 2023-12-05 扬森疫苗与预防公司 腺病毒载体及其用途
MX2020004487A (es) 2017-10-31 2020-08-13 Janssen Vaccines & Prevention Bv Adenovirus y usos de estos.
SG11202003290RA (en) 2017-10-31 2020-05-28 Janssen Vaccines & Prevention Bv Adenovirus and uses thereof
US10953089B1 (en) 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations
AU2021213108A1 (en) * 2020-01-28 2022-08-18 Modernatx, Inc. Coronavirus RNA vaccines
CN116096732A (zh) 2020-01-31 2023-05-09 贝斯以色列护理医疗中心有限公司 用于预防和治疗冠状病毒感染的组合物和方法-sars-cov-2疫苗
EP4149538A1 (en) * 2020-05-11 2023-03-22 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
US10906944B2 (en) 2020-06-29 2021-02-02 The Scripps Research Institute Stabilized coronavirus spike (S) protein immunogens and related vaccines

Also Published As

Publication number Publication date
KR20220134622A (ko) 2022-10-05
US11498944B2 (en) 2022-11-15
TW202204380A (zh) 2022-02-01
EP4097122A1 (en) 2022-12-07
CN116096732A (zh) 2023-05-09
WO2021155323A1 (en) 2021-08-05
EP4097122A4 (en) 2024-07-17
US20210246170A1 (en) 2021-08-12
US20210388032A1 (en) 2021-12-16
US20230075527A1 (en) 2023-03-09
BR112022014808A2 (pt) 2022-09-20
US11384122B2 (en) 2022-07-12
JP2023512519A (ja) 2023-03-27

Similar Documents

Publication Publication Date Title
UY39060A (es) Composiciones y métodos para prevenir y tratar la infección por coronavirus - vacunas sars-cov-2
BR112022014627A2 (pt) Vacina contra coronavírus
MX2023007574A (es) "vacuna de arn contra variantes de sars-cov-2.
BR112022019781A2 (pt) Vacina para o coronavírus
CL2024000409A1 (es) Ácidos nucleicos recombinantes que codifican una o más proteínas cosméticas para usos estéticos.
WO2019193183A3 (en) Novel yellow fever nucleic acid molecules for vaccination
MX2018014573A (es) Vacuna contra el virus del zika.
MX2023000411A (es) Vacuna combinada de sars-cov-2 e influenza.
UY26783A1 (es) Antígenos de estreptococo.
AR124928A2 (es) Vacuna de herpesvirus-1 equino recombinante que contiene glicoproteína c mutada y usos de la misma
BR112020016454A8 (pt) Tratamento utilizando rna que codifica citocina
AR081809A1 (es) Composiciones farmaceuticas que comprenden un polipeptido que comprende al menos un motivo cxxc y antigenos heterologos y usos de las mismas
BR112022016992A2 (pt) Vacina com base em poxvírus recombinante contra ví-rus sars-cov-2
BR112022005687A2 (pt) Vacinas contra o hbv e métodos para tratar o hbv
BR112018075440A2 (pt) composições e métodos para prevenir e tratar a infecção por zika vírus
WO2023094713A3 (en) Coronavirus vaccine
AR109538A1 (es) Vacuna contra la gripe porcina
BR112022016507A2 (pt) Vacinas contra o coronavírus e métodos de uso
AR094725A1 (es) Parvovirus 5a porcino, métodos de uso y vacuna
BR112022022859A2 (pt) Vacinas contra sars-cov-2
BR112022011885A2 (pt) Molécula de ácido nucleico, composição imunogênica, peptídeo, e, métodos para induzir uma resposta imune e para tratar ou prevenir uma patologia
BR112022016893A8 (pt) Vacina contra a infecção do vírus da peste suína africana
UY39464A (es) Composiciones y métodos para la prevención y/o tratamiento de la covid-19
BR112022026580A2 (pt) Composições e métodos para induzir uma resposta imune contra coronavírus
WO2022103929A3 (en) Nucleic acids, proteins, and vaccines of sars-cov-2